An investigational, fully human monoclonal antibody called ACZ885 (canakinumab) provided better pain relief in treating severe gouty arthritis, and it reduced the risk of new attacks by up to 68% compared with an injectable steroid (triamcinolone acetonide), according to results of 2 phase 3 trials announced by Novartis, the drug?s manufacturer.
An investigational, fully human monoclonal antibody called ACZ885 (canakinumab) provided better pain relief in treating severe gouty arthritis, and it reduced the risk of new attacks by up to 68% compared with an injectable steroid (triamcinolone acetonide, TA), according to results of 2 phase 3 trials announced by Novartis, the drug’s manufacturer.
The studies involved more than 450 patients who met the American College of Rheumatology (ACR) criteria for acute gouty arthritis, had suffered from three or more gouty arthritis attacks in the previous 12 months, and for whom the standard anti-inflammatory therapies, nonsteroidal anti-inflammatory drugs (NSAIDs) or colchicine were inadequate or inappropriate.
Patients were randomly assigned to receive a single dose subcutaneous injection of ACZ885 150 mg or an intramuscular injection of TA 40 mg. In the case of a new attack, patients received a new dose of the same treatment they were randomly assigned to at baseline. Primary end points in both studies were pain intensity at 72 hours post-dose, and time to the first new gouty arthritis attack. The Visual Analog Scale, an internationally recognized pain scale, was used to measure pain in the affected joint.
Results showed that ACZ885 reduced pain by an additional -11.4 mm (P=.0005) in 1 study and by -9.8 mm in the second (P=.0018), compared to TA. ACZ885 also significantly reduced the risk of suffering a new gouty arthritis attack within 3 months by 55% in 1 study (P=.0014) and 68% in the second (P<0.0001), compared to TA.
“We are very excited about these results, which indicate that ACZ885 may become a significant new alternative for gouty arthritis patients where many standard anti-inflammatory treatments are inadequate or inappropriate,” said David Epstein, head of the Pharmaceuticals Division of Novartis in a company press release. “Novartis is committed to meeting this unmet medical need and to further investigating the potential of ACZ885 in a number of other conditions where interleukin-1 beta may play a role.”
Regulatory filings for the use of ACZ885 in gouty arthritis patients with limited treatment options were submitted in the EU in 2010 and in the United States, Canada, and Switzerland in the first quarter of 2011.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.